Literature DB >> 12932603

Long-term statin use and psychological well-being.

Yinong Young-Xu1, K Arnold Chan, James K Liao, Shmuel Ravid, Charles M Blatt.   

Abstract

OBJECTIVES: We sought to study the effect of long-term statin use on psychometric measures in an adult population with underlying coronary artery disease (CAD).
BACKGROUND: Previous studies have suggested associations between cholesterol lowering and psychological well-being.
METHODS: Study subjects were recruited from an outpatient cardiology clinic. Psychological well-being was assessed at baseline and annually during follow-up. The exposure of interest was long-term statin use and the outcomes of interest were depression, anxiety, and hostility. We estimated the odds ratios (ORs) and 95% confidence intervals (CI) that represented the strength of association between statin use (vs. no use of any cholesterol-lowering drug) and the risk of having abnormal depression, anxiety, and hostility scores.
RESULTS: Study subjects had an average follow-up of four years and maximum of seven years. Comparing the 140 patients who had continuous use of statins with the 231 patients who did not use any cholesterol-lowering drugs, statin use was associated with lower risk of abnormal depression scores (OR 0.63, 95% CI 0.43 to 0.93), anxiety (OR 0.69, 95% CI 0.47 to 0.99), and hostility (OR 0.77, 95% CI 0.58 to 0.93) after adjustment for the propensity for statin use and potential confounders. The beneficial psychological effects of the statins appeared to be independent of the drugs' cholesterol-lowering effects.
CONCLUSIONS: Long-term use of statins among patients with CAD appeared to be associated with reduced risk of anxiety, depression, and hostility.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12932603      PMCID: PMC2673913          DOI: 10.1016/s0735-1097(03)00785-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  33 in total

1.  Risk of macular degeneration in users of statins: cross sectional study.

Authors:  N F Hall; C R Gale; H Syddall; D I Phillips; C N Martyn
Journal:  BMJ       Date:  2001-08-18

2.  Updated guidelines for cholesterol management.

Authors:  M S Lauer; P B Fontanarosa
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

3.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

4.  Alzheimer's disease. Bad for the heart, bad for the mind?

Authors:  J Marx
Journal:  Science       Date:  2001-10-19       Impact factor: 47.728

5.  Development and validation of the health locus of control (HLC) scale.

Authors:  B S Wallston; K A Wallston; G D Kaplan; S A Maides
Journal:  J Consult Clin Psychol       Date:  1976-08

6.  The Social Readjustment Rating Scale.

Authors:  T H Holmes; R H Rahe
Journal:  J Psychosom Res       Date:  1967-08       Impact factor: 3.006

7.  Exercise performance-based outcomes of medically treated patients with coronary artery disease and profound ST segment depression.

Authors:  C A Thompson; S Jabbour; R J Goldberg; R Y McClean; B Z Bilchik; C M Blatt; S Ravid; T B Graboys
Journal:  J Am Coll Cardiol       Date:  2000-12       Impact factor: 24.094

8.  Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin.

Authors:  J R Downs; M Clearfield; H A Tyroler; E J Whitney; W Kruyer; A Langendorfer; V Zagrebelsky; S Weis; D R Shapiro; P A Beere; A M Gotto
Journal:  Am J Cardiol       Date:  2001-05-01       Impact factor: 2.778

9.  Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials.

Authors:  M F Muldoon; S B Manuck; K A Matthews
Journal:  BMJ       Date:  1990-08-11

10.  Social networks, host resistance, and mortality: a nine-year follow-up study of Alameda County residents.

Authors:  L F Berkman; S L Syme
Journal:  Am J Epidemiol       Date:  1979-02       Impact factor: 4.897

View more
  34 in total

Review 1.  Psychosocial factors and coronary heart disease.

Authors:  Anders G Olsson
Journal:  Curr Atheroscler Rep       Date:  2004-01       Impact factor: 5.113

Review 2.  Pleiotropic effects of statins.

Authors:  James K Liao; Ulrich Laufs
Journal:  Annu Rev Pharmacol Toxicol       Date:  2005       Impact factor: 13.820

Review 3.  A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods.

Authors:  Til Stürmer; Manisha Joshi; Robert J Glynn; Jerry Avorn; Kenneth J Rothman; Sebastian Schneeweiss
Journal:  J Clin Epidemiol       Date:  2005-10-13       Impact factor: 6.437

Review 4.  Lipid-lowering drugs.

Authors:  K Pahan
Journal:  Cell Mol Life Sci       Date:  2006-05       Impact factor: 9.261

5.  Psychologic disorders and statin use: a propensity score-matched analysis.

Authors:  Ishak Mansi; Christopher R Frei; Mary J Pugh; Eric M Mortensen
Journal:  Pharmacotherapy       Date:  2013-04-26       Impact factor: 4.705

Review 6.  Statins, mood, sleep, and physical function: a systematic review.

Authors:  Kristopher J Swiger; Raoul J Manalac; Michael J Blaha; Roger S Blumenthal; Seth S Martin
Journal:  Eur J Clin Pharmacol       Date:  2014-10-08       Impact factor: 2.953

Review 7.  Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.

Authors:  Marco Tuccori; Sabrina Montagnani; Stefania Mantarro; Alice Capogrosso-Sansone; Elisa Ruggiero; Alessandra Saporiti; Luca Antonioli; Matteo Fornai; Corrado Blandizzi
Journal:  CNS Drugs       Date:  2014-03       Impact factor: 5.749

Review 8.  Association of Microvascular Dysfunction With Late-Life Depression: A Systematic Review and Meta-analysis.

Authors:  Marnix J M van Agtmaal; Alfons J H M Houben; Frans Pouwer; Coen D A Stehouwer; Miranda T Schram
Journal:  JAMA Psychiatry       Date:  2017-07-01       Impact factor: 21.596

9.  Increased Serum PAI-1 Levels in Subjects with Metabolic Syndrome and Long-Term Adverse Mental Symptoms: A Population-Based Study.

Authors:  Anne Huotari; Soili M Lehto; Leo Niskanen; Karl-Heinz Herzig; Jukka Hintikka; Heli Koivumaa-Honkanen; Tommi Tolmunen; Kirsi Honkalampi; Noora Kaikkonen; Heimo Viinamäki
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-03-14

10.  Cardiovascular drugs and the risk of suicide: a nested case-control study.

Authors:  Torbjörn Callréus; Ulla Agerskov Andersen; Jesper Hallas; Morten Andersen
Journal:  Eur J Clin Pharmacol       Date:  2007-03-20       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.